Evusheld Appears Less Effective Against Omicron for Patients With Blood Cancer
A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.
A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
Results from the phase 3 QuANTUM-First trial have the potential to change standard care for adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia, according to the lead study author.
Researchers sought to determine whether ASTX727 with venetoclax would be effective in patients with AML.
All patients with cardiotoxicity recovered within 2 months.
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
Researchers sought to determine whether momelotinib would improve outcomes in patients with anemic myelofibrosis compared with danazol.
Researchers sought to determine whether TP53 mutations would be linked with more aggressive disease in patients with MDS or AML.
Researchers sought to determine the relevance of the RAD21 gene in pediatric lymphoblastic leukemia or lymphoma.